Lucira Health, Inc. (LHDX) 

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lucira Health, Inc. (“Lucira” or the “Company”) (NASDAQ: LHDX). The investigation concerns whether Lucira and certain of its officers and/or directors have violated federal securities laws.

 

On October 8, 2021, pre-market, Lucira issued a press release reporting that its supply partner Copan Italia SPA announced a recall of its FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit.  The press release stated that “[a]ccording to Lucira’s records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021,” and that the recalled Copan swabs should not be used and should be disposed.  On this news, Lucira’s stock price dropped sharply during intraday trading on October 8, 2021, damaging investors.

 

If you are aware of any facts relating to this investigation, or purchased Lucira shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.